Xingming Ye

470 total citations
9 papers, 365 citations indexed

About

Xingming Ye is a scholar working on Oncology, Cancer Research and Molecular Biology. According to data from OpenAlex, Xingming Ye has authored 9 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Cancer Research and 2 papers in Molecular Biology. Recurrent topics in Xingming Ye's work include Inflammatory Biomarkers in Disease Prognosis (3 papers), HER2/EGFR in Cancer Research (2 papers) and Cancer, Lipids, and Metabolism (2 papers). Xingming Ye is often cited by papers focused on Inflammatory Biomarkers in Disease Prognosis (3 papers), HER2/EGFR in Cancer Research (2 papers) and Cancer, Lipids, and Metabolism (2 papers). Xingming Ye collaborates with scholars based in China and Austria. Xingming Ye's co-authors include Wendong Bai, Angang Yang, Lintao Jia, Huayu Zhu, Ying Chen, Jing Jia, Lu Lin, Xiongwei Zheng, Lei Wang and Ying Chen and has published in prestigious journals such as The FASEB Journal, Biochemical and Biophysical Research Communications and Oncotarget.

In The Last Decade

Xingming Ye

9 papers receiving 364 citations

Peers

Xingming Ye

CR

MB

ONCOL

OG

PARAS

Miłosz Wilczyński Poland

Shuai Fang China

Cecilia Egoavil Spain

Kaiwu Xu China

Katharina Pracht Germany

Koichi Higaki Japan

Benjamin Vicinus Germany

Takeshi Nagamatsu Japan

Hossein Pashaiefar Iran

Sidrah Shah United Kingdom

Miłosz Wilczyński Poland

Xingming Ye

131 ×0.6

CR

140 ×0.6

MB

63 ×0.5

ONCOL

71 ×2.4

OG

2 ×0.1

PARAS

Citations per year, relative to Xingming Ye Xingming Ye (= 1×) peers Miłosz Wilczyński

Countries citing papers authored by Xingming Ye

Since Specialization

Citations

This map shows the geographic impact of Xingming Ye's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xingming Ye with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xingming Ye more than expected).

Fields of papers citing papers by Xingming Ye

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xingming Ye. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xingming Ye. The network helps show where Xingming Ye may publish in the future.

Co-authorship network of co-authors of Xingming Ye

This figure shows the co-authorship network connecting the top 25 collaborators of Xingming Ye. A scholar is included among the top collaborators of Xingming Ye based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Xingming Ye. Xingming Ye is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

9 of 9 papers shown

1.

Chen, Shanshan, Shijia Liu, Xingming Ye, et al.. (2024). IL-21- and CXCL9-engineered GPC3-specific CAR-T cells combined with PD-1 blockade enhance cytotoxic activities against hepatocellular carcinoma. Clinical and Experimental Medicine. 24(1). 204–204. 5 indexed citations

2.

Ye, Xingming, et al.. (2024). BCAR4 facilitates trastuzumab resistance and EMT in breast cancer via sponging miR ‐665 and interacting with YAP1. The FASEB Journal. 38(7). e23589–e23589. 1 indexed citations

3.

Wang, Lin, Jun Xiao, Minzhe Li, et al.. (2020). <p>Performance of a Nomogram Based on the Integration of Inflammation Markers with Tumor Staging in Prognosis Prediction of Stage III Colorectal Cancer</p>. Cancer Management and Research. Volume 12. 7077–7085. 1 indexed citations

4.

Bai, Wendong, et al.. (2018). Long non-coding RNA UCA1 desensitizes breast cancer cells to trastuzumab by impeding miR-18a repression of Yes-associated protein 1. Biochemical and Biophysical Research Communications. 496(4). 1308–1313. 57 indexed citations

5.

Wang, Lin, Jing Jia, Lu Lin, et al.. (2017). Predictive value of hematological markers of systemic inflammation for managing cervical cancer. Oncotarget. 8(27). 44824–44832. 48 indexed citations

6.

Jia, Jing, Xiongwei Zheng, Ying Chen, et al.. (2015). Stage-dependent changes of preoperative neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in colorectal cancer. Tumor Biology. 36(12). 9319–9325. 45 indexed citations

7.

Ye, Xingming, Huayu Zhu, Wendong Bai, et al.. (2014). Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R. BMC Cancer. 14(1). 134–134. 98 indexed citations

8.

Ye, Xingming, Wendong Bai, Huayu Zhu, et al.. (2014). MiR-221 promotes trastuzumab-resistance and metastasis in HER2-positive breast cancers by targeting PTEN. BMB Reports. 47(5). 268–273. 83 indexed citations

9.

Chen, Yu, Jianming Ding, Junfu Chen, et al.. (2003). An evaluation of the serological and epidemiological effects of the outer envelope vaccine to leptospira.. PubMed. 66(4). 224–30. 27 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact